Editor – Pre-operative preparation with alpha receptor antagonists before phaeochromocytoma resection is established endocrine practice.1 We therefore read with great interest the report by Faloon et al2 detailing circumstances which precluded this. We congratulate them on the successful outcome of the case and for highlighting the ongoing absence of parenteral preparations of alpha blockers in the UK. This has significant implications for the management of a phaeochromocytoma crisis given the uniformity with which these agents are recommended in society guidelines.1,3
The established mantra of alpha followed by beta blockade, whilst correct and widely held, is not achievable in the situation described. A range of alternative intravenous anti-hypertensive agents have been used in the management of phaeochromocytoma. Indeed, some units do not use alpha blockers even when available, but utilise the dihydropyridine calcium-channel blocker nicardipine4 which acts by preventing catecholamine-stimulated calcium influx into arterial smooth muscle. The combined α1 and β antagonist labetalol has also been used5 and has the advantages of familiarity with acute care physicians and accessibility in the emergency department. However, like all beta blockers, concerns exist regarding the risk of paradoxical hypertension in spite of its α1 activity and adverse events have been reported.6 Other drugs that also have a role are magnesium,7 sodium nitroprusside and glyceryl trinitrate.
Use of these agents may be limited by profound hypotension as they were in this case and this serves as an important reminder that patients with phaeochromocytoma are severely volume contracted due to alpha-mediated vasoconstriction. Volume expansion is therefore a key component to acute management and significant hypotension may follow successful tumour (and therefore catecholamine) removal.
We would like to remind readers that alternative parenteral treatment agents for this rare but life-threatening clinical situation are available in the UK.
References
- 1.Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915–42. [DOI] [PubMed] [Google Scholar]
- 2.Faloon S, Venkataraman H, Skordilis K, et al. Lesson of the month 2: Blunt abdominal trauma: atypical presentation of phaeochromocytoma. Clin Med 2018;18:345–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College Of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 2018;71:1269–324. [DOI] [PubMed] [Google Scholar]
- 4.Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 2005;60:439–44. [DOI] [PubMed] [Google Scholar]
- 5.Poopalalingam R, Chin EY. Rapid preparation of a patient with pheochromocytoma with labetolol and magnesium sulfate. Can J Anaesth 2001;48:876–80. [DOI] [PubMed] [Google Scholar]
- 6.Kuok C-H, Yen C-R, Huang C-S, Ko Y-P, Tsai P-S. Cardiovascular collapse after labetalol for hypertensive crisis in an undiagnosed pheochromocytoma during cesarean section. Acta Anaesthesiol Taiwanica 2011;49:69–71. [DOI] [PubMed] [Google Scholar]
- 7.James MF. Use of magnesium sulphate in the anaesthetic management of phaeochromocytoma: a review of 17 anaesthetics. Br J Anaesth 1989;62:616–23. [DOI] [PubMed] [Google Scholar]